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BACKGROUND: Degenerative cervical myelopathy (DCM) involves spinal cord
compression, which causes neurological decline. Neurological impairment in DCM is
variable and can involve complex upper limb dysfunction including loss of manual
dexterity, hyperreflexia, focal weakness, and sensory impairment. The modified Japanese
Orthopaedic Association (mJOA) score relies on the patients’ subjective perceptions,
whereas existing objective measures such as strength and sensory testing do not capture
subtle changes in dexterity and function.
OBJECTIVE: 1) To characterize arm and hand function in DCM; and 2) To develop
and validate Graded Redefined Assessment of Strength, Sensibility, and Prehension
Version-Myelopathy (GRASSP-M), a clinical assessment that quantifies upper limb
impairment.
METHODS:A total of 148DCMpatients (categorized intomild,moderate, and severe based
onmJOA grade) and 21 healthy subjects were enrolled. A complete neurological exam, the
mJOA, the QuickDASH, grip dynamometry, and the GRASSP-M were administered.
RESULTS: Strength, sensation, andmanual dexterity significantly declinedwith increasing
DCM severity (P ≤ .05). Impairment in hand dexterity showed better discrimination
between mild, moderate, and severe DCM categories than strength or sensation. The
GRASSP-Mwas found to be both a reliable (intraclass correlation coefficient>0.75 for intra-
and inter-rater reliability) and valid (with both concurrent and construct validity) tool.
CONCLUSION: These results demonstrate that patients’ subjective reporting of functional
status, especially in the mild DCM category, may underrepresent the extent of functional
impairment. The GRASSP-M is an objective tool designed to characterize patients’
functional impairment related to the upper limb, which proves useful to diagnose and
quantify mild dysfunction, monitor patients for deterioration, and help determine when
patients should be treated surgically.
KEY WORDS: Degenerative cervical myelopathy, Upper limb, Impairment, Function, Disability, Hand function,
Outcomemeasure
Neurosurgery 0:1–8, 2019 DOI:10.1093/neuros/nyz499 www.neurosurgery-online.com
D egenerative cervical myelopathy (DCM)is an overarching term used to describean array of degenerative changes that
narrow the spinal canal and compress the
ABBREVIATIONS: CI, confidence interval; DCM, degenerative cervical myelopathy; GRASSP, Graded Redefined
Assessment of Strength, Sensibility, and Prehension; ICC, intraclass correlation coefficient; MRI, magnetic
resonance imaging;mJOA,modified Japanese Orthopaedic Association
spinal cord.1-3 Patients with DCM usually
present with at least one of the following
symptoms: weakness and/or numbness of
the upper limbs, reduced manual dexterity,
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unstable gait, neuropathic pain, and bladder dysfunction. In
addition, they can present with at least one of the following
neurological signs: hyperreflexia, positive Hoffman’s sign, positive
plantar response, long tract signs, intrinsic handmuscle weakness,
and lower limb spasticity. Functional impairment in these patients
can significantly reduce independence and quality of life.3-6
Recent guidelines have recommended surgical decompression as
the preferred treatment strategy for patients with moderate to
severe DCM.7-13 Patients with mild myelopathy, however, may
benefit from a trial of non-operative intervention provided their
disease is stable.10
Cardinal symptoms of DCM include impaired manual
dexterity and weakness of the intrinsic hand muscles.4,8 As
such, characterizing hand function is essential for under-
standing the natural history of the disease and defining optimal
management strategies, especially in patients with mild DCM.
Several studies have indicated that the refined components of
hand function are not always responsive to decompressive surgery
and that manual dexterity may not completely recover to baseline
following treatment.14-16 Dexterity is a complex function that is
difficult to objectively quantify. Although the modified Japanese
Orthopaedic Association (mJOA) score includes an upper limb
motor and sensory subscore, it is a coarse self-reported measure
that does not fully define a patient’s functional impairment or
hand deficits.17
A barrier in defining DCM management is the lack of
an assessment tool that can characterize the motor, sensory,
and dexterity changes that occur in the hand following cord
compression. To fill this critical knowledge gap, we conducted
an observational cross-sectional study to characterize upper limb
function and hand impairment in patients with mild, moderate,
and severe DCM, and develop and validate a sensitive and specific
assessment tool to better quantify upper limb impairment in
these patients. The sensitivity and psychometric properties of
the Graded Redefined Assessment of Strength, Sensibility, and
Prehension – Version Myelopathy (GRASSP-M) were assessed.
METHODS
Study Design
A single-center, observational, cross-sectional study was conducted
at Toronto Western Hospital between May 2013 and December 2016.
Research ethics board approval was obtained and informed consent was
provided by participating patients.
Patients were enrolled in this study if they satisfied the following
criteria: 1 or more signs of myelopathy (corticospinal motor deficits,
hand atrophy, hyperreflexia, a positive Hoffman sign, upgoing plantar
reflexes, lower limb spasticity, and/or gait ataxia); 1 or more symptoms of
myelopathy (numb hands, clumsy hands, gait impairment, bilateral hand
paresthesia, L’Hermitte’s phenomena, and/or weakness); and evidence
of compression of the spinal cord on magnetic resonance imaging
(MRI). Patients were excluded if their upper limb deficit could not
be entirely explained by cervical cord compression (focal neurological
comorbidities such as stroke, multiple sclerosis, rheumatoid arthritis,
brachial plexus injury, and peripheral neuropathies); they were unable to
speak English; or they were medically unstable. Furthermore, individuals
with a diagnosis of diabetes and no clinical evidence of neuropathy were
included as well as individuals with hypertension. Healthy controls were
recruited through the clinical research team’s networks, patients who
presented to the spine program with no cervical or upper limb deficits,
and clinicians at the hospital that were above the age of 45. There was
an emphasis on recruiting control subjects that would serve as an age-
matched control group.
Severity of functional impairment was classified using the mJOA
scale. Patients were stratified into mild (mJOA = 15-17), moderate
(mJOA = 12-14), and severe (mJOA < 12) groups.10,11 Data
were collected from each patient, including demographic infor-
mation, findings from a neurological exam, mJOA, QuickDASH, grip
dynamometry, and GRASSP-M scores. Grip strength was measured
3 times and results were averaged across trials. Videotaped GRASSP-
M prehension/dexterity tasks were reviewed and independently scored
by 2 assessors (blinded to DCM severity), and inter-rater reliability
was computed (n = 44). A subset of patients were asked to perform
the prehension/dexterity task 2 times in 1 day; a single assessor
scored both performances, and intra-rater reliability data were evaluated
(n= 31). Reliability of the strength and sensation subtests was previously
assessed.18
Scales/Outcomes
The mJOA scale consists of 4 categories: motor dysfunction of the
upper limbs (5 points) and lower limbs (7 points), sensory impairment
of the upper limbs (3 points), and bladder dysfunction (3 points).
A score of 18 represents no functional deficit. The QuickDASH is a
measure of self-perceived disability (patient reported outcome), which
evaluates symptoms associated with upper limb, neck, and muscu-
loskeletal disorders; the higher the score, the greater the disability.19 Grip
dynamometry measures handgrip force; greater force equates to greater
strength.20,21 GRASSP-M evaluates hand impairment through strength,
sensation, and prehension/dexterity subtests; scores closer to zero demon-
strate greater deficit.
Modifications to the GRASSP Version 1.0
The GRASSP Version 1.0 (GRASSP-V1; Neural Outcomes, Toronto,
Canada) is a reliable and valid outcome measure originally developed to
measure upper limb impairment in patients with traumatic tetraplegia.
This tool is sensitive in detecting the sensory, motor, and functional
changes that occur within 1 yr following injury18,22; however, it is not
sensitive enough to capture the upper limb deficits in DCM patients. As
a result, the following modifications were made to the GRASSP-V1 to
increase its applicability in patients with DCM (Figure 1):
a. Sensation: Measurement of upper limb sensation was reduced from
palmar and dorsal sensation to palmar sensation only.
b. Prehension: The GRASSP-M was developed to specifically analyze
manual dexterity. The prehension portion of GRASSP-V1 consists of
6 prehension tasks scored on a 5-point scale; this section was reduced
to a single task and the scoring was modified to objectively define
dexterous function. These changes give the scale greater sensitivity to
better discriminate dexterity differences among patients with mild,
moderate, and severe DCM.
c. Strength testing was not modified.
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FIGURE 1. Development of the GRASSP-M. This figure defines the domains in the original GRASSP and the reduced domains in the GRASSP-myelopathy.
Analysis
Statistical analysis was performed using SPSS Version 21.0 (IBM,
Armonk, New York). Continuous variables were described using means
and standard deviations, and categorical variables were summarized using
frequencies. The significance level was set at P ≤ .05. Differences
in manual dexterity scores between the dominant and non-dominant
hand were evaluated using paired t-tests. Differences in age and gender
distribution between healthy controls and DCM patients were assessed
using an unpaired 2-way t-test (unequal variance) and chi square test,
respectively. Analysis of variance and/or unpaired 2-way t-tests (unequal
variance) were used to evaluate differences in strength, sensation, and
dexterity between controls and DCM patients, as well as among patients
with mild, moderate, and severe myelopathy.
Inter- and intra-rater reliabilities were calculated using intraclass corre-
lation coefficient (ICC) under the 2-way random effects model; an ICC
of 0.75 was considered acceptable.23
To assess concurrent validity, the following hypothesis was first
generated: the GRASSP-M can discriminate among patients with mild,
moderate, and severe myelopathy but does not perfectly correlate
with the mJOA. Pearson correlation coefficients were computed to
evaluate the association between the GRASSP-M strength, sensation,
and prehension/dexterity subtests and the subscores of the mJOA that
measure upper limb function. A moderate, positive correlation would
demonstrate concurrent validity. Known-groups validity was used to
establish construct validity. Unpaired 2-way t-tests (unequal variance)
with a Bonferroni correction (P ≤ .016) were used to examine whether
patients with mild, moderate, and severe DCM (based on the mJOA)
could be differentiated by their GRASSP-M strength, sensation, and
prehension/dexterity subtest scores.
RESULTS
Sample
A total of 148 study participants and 21 control subjects were
enrolled. The sample consisted of 84 males and 64 females, with
a mean age of 56.89 ± 10.67 yr. Mean duration of symptoms
was 45.5 ± 60.4 mo. The control sample consisted of 11 males
and 10 females, with a mean age of 53.67 ± 16.81 yr. No signif-
icant differences in the age (P = .403) and gender (P = .705)
distribution between healthy controls and DCM patients were
present. The sample consisted of 75mild (mJOA 15.85± 0.748),
41 moderate (mJOA 13.20 ± 0.782), and 32 severe (mJOA
9.94 ± 1.110) patients.
Scores
Table 1 reports baseline mJOA, QuickDASH, grip
strength, and GRASSP-M subtest (strength, sensation, and
prehension/dexterity) scores for DCM patients and controls.
Figure 2 illustrates the dexterity scores of patients with DCM
and controls. GRASSP-M strength scores in the dominant hand
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TABLE 1. Sample Data Stratified bymJOA
Variable
Control (n= 21)
mean (SD)
Mild (n= 75)
mean (SD)
Moderate (n= 41)
mean (SD)
Severe (n= 32)
mean (SD)
Duration of symptoms (months) 0 40.16 (±58.25) 57.62 (±63.36) 41.46 (±61.01)
mJOA (/18) 18 15.85 (±0.748) 13.20 (±0.782) 9.94 (±1.11)
UL mJOA (/8) 8 6.43 (±0.701) 5.29 (±0.901) 4.19 (±0.780)
UL motor mJOA (/5) 5 4.47 (±0.502) 3.59 (±0.631) 2.81 (±0.738)
Sensation mJOA (/3) 3 1.96 (±0.478) 1.71 (±0.512) 1.38 (±0.554)
QuickDASH (%) 0 27.59 (±17.26) 45.07 (±19.83) 62.12 (±22.41)
Grip strength Dominant (Kg) 35.92† 31.00 (±13.34) 27.05 (±19.83) 24.92 (±9.71)
Non-dominant (Kg) 29.60† 30.25 (±12.60) 26.13 (±13.24) 24.38 (±9.05)
GRASSP-M strength Dominant (/50) 50‡ 47.95a,c
(±3.31)
46.34a,b (±3.53) 43.52b,c (±6.33)
Non-dominant (/50) 50‡ 48.17a,c
(±2.586)
46.27a (±5.05) 43.77c (±6.55)
GRASSP-M sensation Dominant (/12) 12‡ 10.73c (±1.87) 10.69b (±1.47) 8.56b,c (±3.26)
Non-dominant (/12) 12‡ 11.03c (±1.65) 10.85b (±1.49) 8.34b,c (±3.28)
GRASSP-M prehension/dexterity Dominant (/9) 8.57d,e,f (±0.676) 7.05a,c,d
(±1.22)
5.95a,b,e (±1.55) 4.66b,c,f (±2.03)
Dominant time (sec) 47.05 (±22.41) 52.71a,c
(±18.17)
66.93a (±25.39) 84.06c (±45.53)
Non-dominant (/9) 8.62d,e,f (±0.669) 6.58a,c,d
(±1.31)
5.54a,b,e (±1.55) 4.23b,c,f (±1.82)
Non-dominant time (sec) 50.52d,e,f (±14.97) 60.21a,c,d
(±18.91)
72.61a,b,e (±23.18) 94.13b,c,f (±44.73)
aIndicates statistical significance between mild and moderate groups (P ≤ .05).
bIndicates statistical significance between moderate and severe groups (P ≤ .05).
cIndicates statistical significance between mild and severe groups (P ≤ .05).
dIndicates statistical significance between control and mild groups (P ≤ .05).
eIndicates statistical significance between control and moderate groups (P ≤ .05).
fIndicates statistical significance between control and severe groups (P ≤ .05).
†Indicates normative value taken from the literature21.
‡Indicates values expected of healthy controls.
were weaker in patients with moderate (vs mild) and severe
(vs mild and moderate) myelopathy. GRASSP-M sensation
scores were also reduced in patients with severe myelopathy
compared to those with mild and moderate myelopathy in both
the dominant and non-dominant hand. GRASSP-M sensation
scores, however, were not significantly different between patients
with mild and moderate DCM. Finally, GRASSP-M prehension/
dexterity scores were different between controls and patients with
DCM, as well as among patients with mild, moderate, and severe
myelopathy in both the dominant and non-dominant hands.
The mean values in Table 1 were used to set GRASSP-M severity
thresholds.
In a sub-analysis of mild DCM patients, the opponens pollicis,
abductor digiti minimi, first dorsal interossi, and anterior deltoid
muscles consistently demonstrated mild weakness (grade 3 and 4)
(P = 1.69 E-07).
Imaging
All study participants did have a conventional MRI, and we
used signal change and number of levels to describe the sample.
In all, 41% to 48% of each severity group presented with T2
weighted signal change, (48%-mild, 41%-moderate, and 46%-
severe). In all, 3% to 8% of each severity group presented with
T1 weighted signal change, (5%-mild, 3%-moderate, and 8%-
severe). In all, 5% to 17% of each severity group presented
with both T1 and T2 weighted signal change, (5%-mild, 10%-
moderate, and 17%-severe). Within each severity group, 29%
to 42% of the sample had no signal change (42%-mild, 46%-
moderate, and 29%-severe). There is not a large difference
between the mild and moderate groups, whereas severe patients
clearly have greater prevalence of signal change. There was an
increase in the number of levels compressed as patients became
more severe. The prevalence of 1 to 2 level compression for
each severity group ranged from 62% to 30% (62%-mild, 54%-
moderate, and 30%-severe), 3 levels of compression for each
severity group ranged between 11% and 26% (18%-mild, 26%-
moderate, and 11%-severe), and 4 to 5 levels of compression
ranged from 19% to 37% (19%-mild, 20%-moderate, and
37%-severe). Again, the number of levels compressed was
found to have some relationship to severity and some discrim-
inative qualities. In this report of imaging, 22% to 29% of
the imaging was not available for the signal change summary;
however, it was complete for the number of levels compressed
summary.
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FIGURE2. Dexterity scores for healthy controls and patients. This figure demonstrates the discrimination of severity of DCM
compared with healthy controls. The dexterity score defines even the subtle deficit in the mild DCM patient.
Reliability
Table 2 reports the ICC and CI for inter-rater (n = 31) and
intra-rater reliabilities (n = 44). The ICC for inter-rater relia-
bility was 0.869 (95% CI: 0.759-0.928) in the dominant hand
and 0.862 (95% CI: 0.748-0.925) in the non-dominant hand.
The ICC for intra-rater reliability was 0.868 (95% CI: 0.727-
0.936) in the dominant hand and 0.790 (95% CI: 0.565-0.899)
in the non-dominant hand.
Validity
Table 3 shows the Pearson correlation coefficients between
baseline GRASSP-M and mJOA. All GRASSP-M subtests
showed a positive, moderate correlation with the upper limb
motor, upper limb sensory, and total upper limb mJOA scores.
Dexterity time showed a negative, moderate correlation with
these scores. All correlations were significant except for the corre-
lation between dexterity time in the dominant hand and the
mJOA upper limb sensation score. Known groups’ validity is
illustrated in Table 4. The prehension/dexterity score was the
most discriminative subtest of the GRASSP-M, followed by the
strength subscore. Finally, Table 5 defines the thresholds set for
each severity specific to the hand with the GRASSP-M.
DISCUSSION
Although impairment of manual dexterity and weakness of
intrinsic hand muscles are some of the earliest symptoms of
DCM,4,8 upper limb dysfunction has not been adequately charac-
terized. This study aims to fill this knowledge gap by developing
an assessment tool to quantify impairment in hand function. It is
crucial to understand patients’ upper limb deficits at the time of
diagnosis to appropriately determine their clinical plan.11 Proper
patient management requires using gold standard measures, such
as the mJOA, and objective, sensitive clinical tools to define the
different DCM severities. We have presented the characteristics
of upper limb impairment and introduced a new upper limb
tool to the DCM field. We conclude that there are elements
of dysfunction that are currently not captured with standard
DCM assessments, indicating clinical decisions have not always
been based on patients’ true deficits. For example, the traditional
myotomal upper limb exam does not assess the intrinsic hand
muscles,24 which we have shown are impacted early in the disease
process.
The majority of DCM patients in this study reported upper
limb dysfunction, including those with mild DCM. This
finding is consistent with previous studies, which reveal that
upper limb numbness and impaired dexterity are experienced
early in the disease process.2,8,25,26 There was a significant
difference in the prehension/dexterity subtest scores and time
for completion between the patients’ 2 hands; thus, the average
grip dynamometry and GRASSP-M subtest scores for dominant
and non-dominant hands were reported separately. We noted
that strength (GRASSP-M strength), sensation, and dexterity
decreased as severity increased, which is consistent with the liter-
ature.26-28 However, grip strength did not significantly decrease
as severity increased in our sample. We emphasize the importance
of an objective clinical tool that can quantify all aspects of upper
limb impairment, such as the GRASSP-M, in guiding clinical
decision-making.
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TABLE 2. Inter- and Intra-rater Reliability for GRASSP-M Prehension/Dexterity Subtest
Inter-rater reliability Intra-rater reliability
Variable ICC – Cronbach’s alpha CI ICC – Cronbach’s alpha CI
Dominant hand 0.869∗ 0.759-0.928 0.868∗ 0.727-0.936
Non-dominant hand 0.862∗ 0.748-0.925 0.790∗ 0.565-0.899
∗Indicates statistical significance (P ≤ .05).
TABLE 3. Concurrent Validity
Subtest ULmJOA ULmotor mJOA SensationmJOA
GRASSP-M strength Dominant 0.431∗ 0.373∗ 0.323∗
Non-dominant 0.406∗ 0.384∗ 0.251∗
GRASSP-M sensation Dominant 0.412∗ 0.374∗ 0.280∗
Non-dominant 0.488∗ 0.448∗ 0.323∗
GRASSP-M prehension/dexterity Dominant 0.502∗ 0.511∗ 0.250∗
Non-dominant 0.533∗ 0.524∗ 0.301∗
GRASSP-M prehension/dexterity time Dominant − 0.407∗ − 0.455∗ − 0.138
Non-dominant − 0.439∗ − 0.469∗ − 0.186∗
∗Indicates statistical significance (P ≤ .05).
TABLE 4. Discriminative Qualities of GRASSP-M Domains
P-value
Subtest Mild vs moderate Moderate vs severe Mild vs severe
GRASSP-M strength Dominant 0.019 0.028 0.001
Non-dominant 0.028 0.079 0.001
GRASSP-M sensation Dominant 0.883 0.001 0.001
Non-dominant 0.567 0.000 0.000
GRASSP-M prehension/dexterity Dominant 0.000 0.004 0.000
Non-dominant 0.001 0.002 0.000
GRASSP-M prehension/dexterity time Dominant 0.002 0.062 0.001
Non-dominant 0.005 0.019 0.000
(P ≤ .016) refers to a significant difference between groups and the P-value reflects a Bonferroni Correction.
Reliability and Validity
Inter- and intra-rater reliabilities for all GRASSP-M subtests
were high and above our predefined threshold of 0.75. These
results indicate that the GRASSP-M is a reliable tool.
Concurrent validity was evaluated by assessing the correlation
between the GRASSP-M subsets and the mJOA upper extremity
subscores. The GRASSP-M measures subtle changes in hand
function that may not be fully captured by the mJOA. As a result,
we did not expect a strong correlation between all GRASSP-
M subtests and the mJOA subscores. Based on our results, the
majority of GRASSP-M subtests were moderately and signifi-
cantly correlated with the mJOA upper extremity subscores. The
exception to this was the correlation between dexterity time and
mJOA sensation score, which did not reach statistical signifi-
cance. These results demonstrate concurrent validity and indicate
that the GRASSP-M captures aspects of hand function that the
mJOA may not. Furthermore, the GRASSP-M strength and
sensation subtests, as well as the time required to complete the
prehension/dexterity subtest, were able to discriminate among
patients with mild, moderate, and severe DCM. These results
support the use of the GRASSP-M as an adjuvant tool for the
assessment of dexterity function and disease progression.
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TABLE 5. GRASSP-M Discriminative Values for Assessment of DCM
GRASSP-M Control Mild Moderate Severe
GRASSP-Str (0-50) 50 48-46 note which muscles 45-40 Less than 40
GRASSP-Sens (0-12) 11-12 10 9-8 Less than 8
GRASSP-PD (0-9) 8-9 8-7 6-5 Less than 5
GRASSP-M
Through this study we characterized hand impairment
in DCM and also set discriminative thresholds related to
impairment. The initial step was to define discriminative qualities
of the new measures in relation to the mild, moderate, and severe
sub-groupings defined by the mJOA. The mean was used as the
primary value to define the thresholds for mild, moderate, and
severe (Table 1). The thresholds in Table 5 can be used to define
severity specific to the hand and upper limb. The dexterity score
is the most useful subtest; it can be used to confirm the mJOA
severity or determine if there is more loss of function specific to
the hand than a mild patient should present with.
Insights Into Mild DCM
The opponens pollicis, abductor digiti minimi, first dorsal
interossei, and anterior deltoid muscles demonstrated significant
weakness early in the disease process. These findings are not
surprising, as weakness of the intrinsic hand muscles is one
of the first symptoms of DCM.14,15 Furthermore, the anterior
deltoid muscle often activates during movement of intrinsic hand
muscles29,30; as a result, concomitant impairment of the anterior
deltoid and intrinsic hand muscles was observed. These results
suggest that assessing intrinsic hand muscles is as important as
evaluating the larger muscle groups, especially in patients with
mild DCM. Therefore, in addition to the traditional C5-T1
myotomal testing, these 4 muscles should be tested to elucidate
the level of impairment in patients with mild DCM.
This study also demonstrated that a proportion of patients
classified as mild on the mJOA in fact have moderate impairment
of dexterity. With the GRASSP-M, patients with moderate DCM
scored, on average, a 5.95/9 and 5.54/9 on their dominant
and non-dominant hands, respectively. As such, a score ≤5
is likely representative of moderate dexterity impairment. In
the mild cohort, 28% of patients scored a ≤5/9 on the
prehension/dexterity subtest with at least 1 hand; these mild
patients actually presented with moderately impaired dexterity.
Recent guidelines have recommended surgical treatment for mild
DCM patients with progressive myelopathy to prevent further
neurologic deterioration and optimize outcomes.10 Given these
guidelines, it is important to differentiate between patients who
are likely to progress and those who may benefit from a trial of
nonoperative therapy. Patients who present with a greater degree
of functional impairment are likely at a higher risk of neurological
decline and may be candidates for surgery.31 Assessment using the
GRASSP-M could help to determine which mild patients have
moderate levels of functional hand impairment and should be
counseled for surgical intervention.
Limitations
We excluded patients with focal neurological comorbidities
such as stroke, multiple sclerosis, rheumatoid arthritis, brachial
plexus injury, and peripheral neuropathies, as these comorbidities
may cause similar deficits as DCM. However, we did not exclude
patients with diabetes, hypertension, and osteoarthritis; these
diseases may impact a patient’s total mJOA score. However, by
excluding individuals with pathologies affecting the upper limbs,
we reduced the impact or influence of any other disease on this
sample. Another limitation is that although a control sample was
recruited and tested, some comparative variables were defined by
the existing medical literature. In particular, grip strength for the
sample was compared to normative values defined in the medical
literature. Published normative values are typically based on a
sample specifically collected to reflect normal values, and we felt
our control sample was not superior to this study. With respect
to GRASSP domains of strength and sensation, we compare the
impaired group to expected normal values, which is represented
by the highest score. The GRASSP is designed to score with
respect to normal, which is the maximum score on each scale.18
It is also important to note that hand dysfunction and upper
extremity deficits are only one aspect of the impairments that
individuals with DCM present with. Gait deficits also play a
significant role in their global disability, and while we do not
report on gait in this paper, many of the mild DCM study partic-
ipants and all of the moderate and severe individuals did present
with some gait impairment. The gait impairment findings will be
reported in a separate study. Finally, it is important to mention
that this study was conducted at a single center, which may
introduce selection bias.
CONCLUSION
The GRASSP-M can objectively quantify hand impairment
and can assess DCM severitymore accurately than the widely used
subjective measures. This information allows for earlier diagnosis
of DCM, improved patient monitoring, and treatment planning.
This study has demonstrated that the GRASSP-M is a valid and
reliable tool for quantifying fine motor skill dysfunction in a
clinical setting. As a result, we recommend that clinicians use the
GRASSP-M to assess and monitor patients with DCM, regardless
of whether they are candidates for surgery. The GRASSP-M can
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be administered by any clinician with good assessment skills,
and the test can be performed in 10 to 15 min, providing
useful diagnostic information for the clinical team. Unification
of outcome assessment will allow the field to accurately quantify
the progression of DCM and prognosticate treatment outcomes.
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